Trial Profile

Phase 1 study of DNase armored CAR T cell therapies combined with immune checkpoint inhibitors or chemotherapy as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DNase-armored-CAR-T-cell-therapies-Xenetic-Biosciences/CLS-Therapeutics (Primary) ; Antineoplastics; Immune checkpoint protein inhibitors
Indications Carcinoma; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man

13 Nov 2024 According to a Xenetic Biosciences media release, company continues to advance its DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.
09 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com